AHCO
AdaptHealth Corp.10.35
+0.08+0.78%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.40BP/E (TTM)
18.82Basic EPS (TTM)
0.55Dividend Yield
0%Recent Filings
8-K
Exclusive HME partnership announced
AdaptHealth Corp. signed a 5-year exclusive agreement on August 5, 2025, to supply home medical equipment to a major national healthcare system's network, covering over 10 million members via a capitation model for Medicare Advantage, Medicaid, and private insurance. This deal bolsters non-acquired growth by aligning AdaptHealth's tech-enabled services with the system's innovative care. It spans sleep, respiratory, diabetes, and wellness products. Risks include potential termination provisions and regulatory uncertainties.
8-K
AdaptHealth Q2 revenue dips slightly
AdaptHealth reported Q2 2025 net revenue of $800.4 million, down 0.7% from $806.0 million last year, with net income falling to $14.7 million from $19.4 million. Adjusted EBITDA dipped 5.9% to $155.5 million, yet the company booked a $32.2 million gain from selling incontinence and infusion assets in its Wellness at Home segment. Sales closed this quarter. Momentum builds through a new capitated partnership and debt reduction. Updated 2025 guidance projects net revenue of $3.18 billion to $3.26 billion and Adjusted EBITDA of $642 million to $682 million.
10-Q
Q2 FY2025 results
AdaptHealth's Q2 revenue dipped 0.7% year-over-year to $800.4M, yet operating income surged 52.3% to $79.3M, fueled by a $32.2M gain from selling two Wellness at Home businesses in May and June for $120.8M total proceeds. Respiratory Health grew 5.6% on stronger oxygen reimbursements, while Sleep Health edged up 0.9% from CPAP resupply sales; Diabetes and Wellness segments softened amid payor shifts and divestitures. Gross margin held at 19.3%, with diluted EPS steady at $0.10 despite a $27.4M discrete tax hit from the sales. Cash stood at $68.6M, free cash flow hit $73.3M (derived), and debt fell to $1.8B after $175M repayments, revolver fully available at $274.5M. Acquisitions added two HME assets for $18.6M cash, recognizing $15.7M goodwill. Securities class actions loom as a key risk.
8-K
Closes infusion assets sale
AdaptHealth closed the sale of certain infusion assets from its Wellness at Home segment earlier in June 2025, shedding $52 million in annual revenue and $5 million in Adjusted EBITDA. The company applied proceeds to prepay $65 million on its term loan, following a $70 million prepayment in May from another asset sale, while projecting $30 million in cash taxes on the gains. This refines its 2025 guidance to $3,150–$3,290 million revenue, $662–$702 million Adjusted EBITDA, and $170–$190 million free cash flow. Debt reduction sharpens focus, yet taxes temper the benefits.
8-K
Annual meeting results announced
AdaptHealth Corp. held its annual stockholder meeting on June 18, 2025, with 93.32% of shares represented. Stockholders elected Terence Connors, Brad Coppens, Ted Lundberg, Dr. Susan Weaver, David Williams III, and Dale Wolf as directors for one-year terms, despite some withheld votes signaling scrutiny. They ratified KPMG LLP as auditors for 2025 and advisory approved executive compensation. All proposals passed, affirming governance continuity.
ADUS
Addus HomeCare Corporation
113.49-1.65
AEMD
Aethlon Medical, Inc.
2.94-0.11
AVAH
Aveanna Healthcare Holdings Inc
8.84-0.05
MASI
Masimo Corporation
134.52-2.88
OMI
Owens & Minor, Inc.
3.10+0.09
QIPT
Quipt Home Medical Corp.
3.52+0.02
RMD
ResMed Inc.
247.34-5.73
RMSL
RemSleep Holdings, Inc.
0.00+0.00
VMD
Viemed Healthcare, Inc.
7.26-0.11
VYCO
Vycor Medical, Inc.
0.16+0.00